Since amphotericin B was isolated in 1955 by Gold, Stout, Pagano, and Donovick,1 numerous papers have reported its beneficial effect in the treatment of systemic mycoses,2-7 including South American blastomycosis.8-10
American (mucocutaneous) leishmaniasis still constitutes a serious problem in certain areas of Brazil and Latin America, the mucous membrane involvement requiring intensive treatment. On the other hand, there is occurrence of frequent cases of relapses and resistance to the usual therapy. For these reasons the unexpected effectiveness of amphotericin B in the treatment of American leishmaniasis constitutes a new hope for the patients suffering from this disease. The usefulness of the drug in the disease was verified simultaneously by Furtado 11 and Lacaz et al.,12 in four and three patients, respectively. The clinical results were confirmed with in vitro studies by Silva,13 who reported the inhibitory effect of amphotericin B against leptomonas in cultures of Leishmania braziliensis
SAMPAIO SAP, GODOY JT, PAIVA L, DILLON NL, LACAZ CDS. The Treatment of American (Mucocutaneous) Leishmaniasis with Amphotericin B. Arch Dermatol. 1960;82(4):627–635. doi:10.1001/archderm.1960.01580040145026
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.